Novartis’ biotech shopping spree stays focused on the low-budget specials of the day
Novartis inked a string of acquisitions in the fourth quarter, but they barely registered on the Big Pharma Richter scale for M&A. There was a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
